(133 days)
No
The document describes a synthetic bone void filler and its physical properties and performance in animal studies. There is no mention of any software, algorithms, or data processing that would indicate the use of AI or ML.
Yes
The device is intended to fill bony voids or gaps of the skeletal system and is resorbed and replaced with bone during the healing process, indicating a therapeutic function in repairing skeletal defects.
No
Explanation: The device, MagnetOs Easypack Putty, is described as a synthetic, resorbable, osteoconductive bone void filler intended to fill bony voids or gaps. Its function is to facilitate healing and bone replacement, not to diagnose a condition or disease.
No
The device is a physical bone void filler made of TCP and HA granules with a polymeric binder, not a software application.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to fill bony voids or gaps in the skeletal system, specifically the posterolateral spine, and to be used with autograft as a bone graft extender. This is a therapeutic and structural purpose within the body.
- Device Description: The device is a synthetic, resorbable, osteoconductive bone void filler made of TCP and HA granules with a binder. It is designed to be implanted directly into the body to facilitate bone healing.
- Lack of In Vitro Testing: The description of performance studies focuses on animal testing (in vivo) and bench testing, not testing of samples taken from the human body (in vitro) for diagnostic purposes.
- No Mention of Diagnostic Purpose: The entire description revolves around the physical and biological function of the material within the body for bone repair, not the analysis of biological samples to diagnose a condition.
IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for the diagnosis, prevention, monitoring, treatment, or alleviation of disease. This device does not fit that description.
N/A
Intended Use / Indications for Use
MagnetOs Easypack Putty is intended to fill bony voids or gaps of the skeletal system, i.e. posterolateral spine. In the posterolateral spine, MagnetOs Easypack Putty must be used with autograft as a bone graft extender. The osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the bony structure.
MagnetOs Easypack Putty resorbs and is replaced with bone during the healing process.
Product codes
MQV
Device Description
MagnetOs Easypack Putty is a synthetic, resorbable, osteoconductive bone void filler for the repair of bony defects.
MagnetOs Easypack Putty consists of 65–75% tri-calcium phosphate (TCP – Ca3(PO4)2) and 25-35% hydroxyapatite (HA - Ca10(PO4)6(OH)2) granules, premixed with a synthetic polymeric binder that provides cohesion between the granules.
New bone will be deposited on the surface of the graft when placed next to viable host bone. The graft resorbs and is replaced by bone during the natural process of bone remodeling.
MagnetOs Easypack Putty is a ready-to-use product. Pressure applied by manipulation allows users to shape MagnetOs Easypack Putty to conform to the contours of bony defects.
MagnetOs Easypack Putty is provided in open-ended syringes in a range of product volumes. MagnetOs Easypack Putty is gamma-sterilized and sterile packaged for single use only.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Skeletal system, posterolateral spine
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Medical/Clinical
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Bench testing and animal data demonstrated that the safety and effectiveness of the MagnetOs Easypack Putty is equivalent to the predicate devices. Testing was performed to evaluate the physicochemical and crystallographic characteristics of MagnetOs Putty through product visual inspection, composition, crystallinity, and Ca/P ratio (X-ray diffraction (XRD)), microstructure (SEM), identity (Fourier Transform Infrared (FTIR) spectroscopy), porosity (mercury intrusion porosimetry), polymer inherent viscosity (Ubbelohde Viscometry), polymer chemical composition (NMR), organic volatile impurities (OVI), water content (Coulometric Karl Fischer Titration), trace elemental analysis (ICP-MS), in vitro dissolution and pH, polymer irrigation test, and calcium ion release (ICP-MS). Biocompatibility was assessed using ISO 10993-1, ISO 10993-3, ISO 10993-5, ISO 10993-6, ISO 10993-10, ISO 10993-11, ISO 10993-12, ISO 10993-18, USP , USO , USP 43 - NF 38 and European Pharmacopeia, 10th edition, 2020. Animal testing was performed in a rabbit posterolateral spine fusion model. Animals were evaluated after implantation with the subject device, the primary predicate device, and autograft (positive control) up to 12 weeks. Evaluation endpoints included manual palpation, range of motion/flexibility testing, plain and high-resolution radiography, micro-computed tomography (micro-CT) imaging, undecalcified histologic evaluation, and histomorphometric analysis. Decalcified paraffin histology sections also were graded according to ISO 10993-6 (Annex E). No clinical studies were conducted.
Key Metrics
Not Found
Predicate Device(s)
K181958, K171563, K193075, K082575, K161859
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
September 2, 2021
Image /page/0/Picture/1 description: The image shows the logos of the Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the FDA acronym in a blue square, followed by the words "U.S. Food & Drug Administration" in blue text. The logos are displayed side-by-side.
Kuros Biosciences B.V. % Angela Paterson Senior Consultant Compliance Solutions Ltd Suite 10, Dunswood House, 1 Dunswood Road, Cumbernauld Glasgow G67 3EN United Kingdom
Re: K211201
Trade/Device Name: MagnetOs Easypack Putty Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable Calcium Salt Bone Void Filler Device Regulatory Class: Class II Product Code: MQV Dated: July 28, 2021 Received: August 3, 2021
Dear Angela Paterson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Laura C. Rose, Ph.D. Assistant Director DHT6C: Division Restorative, Repair and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K211201
Device Name MagnetOs Easypack Putty
Indications for Use (Describe)
MagnetOs Easypack Putty is intended to fill bony voids or gaps of the skeletal system, i.e. posterolateral spine. In the posterolateral spine, MagnetOs Easypack Putty must be used with autograft as a bone graft extender. The osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the bony structure.
MagnetOs Easypack Putty resorbs and is replaced with bone during the healing process.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Kuros Biosciences Traditional 510(k) For MagnetOs Easypack Putty
510(k) Summary
This 510(k) Summary is submitted in accordance with 21 CFR Part 807, Section 807.92.
Submitter's Name:
Kuros Biosciences B.V.
Submitter's Address:
Kuros Biosciences B.V. Prof. Bronkhorstlaan 10, building 48 3723 MB Bilthoven The Netherlands
Establishment Registration Number:
3008147766
Contact Person:
Angela Paterson
Telephone + 44 7884 274 220
Date Prepared:
2nd September 2021
4
Kuros Biosciences Traditional 510(k) For MaqnetOs Easypack Putty
The Device Classification Information regarding MagnetOs Easypack Putty is summarized below.
Primary Product Code:
| Regulation
Number | Device | Device
Class | Product
Code | Classification
Panel |
|----------------------|---------------------------------------------|-----------------|-----------------|-------------------------|
| 888.3045 | Resorbable calcium salt
bone void filler | 2 | MQV | Orthopedic |
Device Trade Name:
MagnetOs Easypack Putty
Device Common Name:
MagnetOs Easypack Putty
Intended Use:
MagnetOs Easypack Putty is intended to fill bony voids or gaps of the skeletal system, i.e., posterolateral spine. In the posterolateral spine, MagnetOs Easypack Putty must be used with autograft as a bone graft extender. The osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure.
MagnetOs Easypack Putty resorbs and is replaced with bone during the healing process.
Summary of Substantial Equivalence:
MagnetOs Easypack Putty is substantially equivalent in indications and design principles to the following cleared and legally marketed predicate devices:
- . MagnetOs Putty (K181958, K171563), the primary predicate, is highly similar to the subiect device used for the comparison animal spine study. It consists of the identical unmodified MagnetOs granules component. which is responsible for the mode of action of the subject device, together with a synthetic polymeric binder, which is highly similar to the binder used in the subject device.
- . Osteo3 ZP Putty (K193075) is packed in identical primary packaging and is indicated for the same intended use as MagnetOs Easypack Putty.
- . Actifuse ABX (K082575) is packed in comparable primary packaging and has similar indications for use, as a bone void filler in spine.
- MagnetOs Granules (Xpand Biotechnology B.V., K161859) is cleared for the same . intended use as MagnetOs Easypack Putty. Identical MagnetOs granules are present in MagnetOs Easypack Putty and MagnetOs Putty.
Note: Xpand Biotechnology B.V. is the previous company name of Kuros Biosciences B.V.
5
Kuros Biosciences Traditional 510(k) For MagnetOs Easypack Putty
The subject device, MagnetOs Easypack Putty, and predicate devices MagnetOs Putty, Osteo3 ZP Putty, Actifuse ABX, and MaqnetOs Granules have the same intended use, the same product classification and product code (MQV) and have similar Indications for Use.
| Property | 510(k) Subject
Device | Primary
Predicate Device | Equivalent
Device | Equivalent
Device | Equivalent
Device |
|--------------------------|------------------------------|------------------------------|----------------------|----------------------|------------------------------|
| Device Name | MagnetOs
Easypack Putty | MagnetOs Putty | Osteo³ ZP
Putty | Actifuse
ABX | MagnetOs
Granules |
| Device
Manufacturer | Kuros
Biosciences
B.V. | Kuros
Biosciences
B.V. | SIRAKOSS
Ltd. | Baxter | Kuros
Biosciences
B.V. |
| 510(k) | No | K181958,
K171563 | K193075 | K082575 | K161859 |
| Device
Classification | II | II | II | II | II |
| Product Code | MQV | MQV | MQV | MQV | MQV |
| Use
Environment | Medical/
Clinical | Medical/
Clinical | Medical/
Clinical | Medical/
Clinical | Medical/
Clinical |
MagnetOs Easypack Putty is substantially equivalent to the predicate devices MagnetOs Putty, Osteo3 ZP Putty, Actifuse ABX, and MagnetOs Granules with respect to design, structure, materials, and mechanism of action, and has similar Indications for Use in posterolateral spine. MagnetOs Putty is the primary predicate device used for animal performance testing studies.
For the three MagnetOs devices, the MagnetOs granules component is identical.
Between the MagnetOs Easypack Putty subject device and the MagnetOs Putty, Osteo3 ZP Putty, Actifuse ABX, and MagnetOs Granules predicate devices, there are limited differences. These aspects do not affect the safety and biocompatibility of MagnetOs Easypack Putty because of the identical nature of the building blocks of these materials and the site of application (bone).
The subject device and the Osteo3 ZP Putty and Actifuse ABX predicate devices are provided in equivalent primary packaging (open-ended syringes).
The granules used in MagnetOs Easypack Putty subject device are identical to the granules used in the MagnetOs Putty primary predicate device. The polymeric binders in these two devices share the same identity. The only difference between the two binders is the slightly different molecular weight to adjust softness. The nature and essential characteristics of the granules remain unaltered when mixed with the polymeric binder.
As a result, MagnetOs Easypack Putty, and all predicate devices, including MagnetOs Granules (which consist of granules alone, without a binder/carrier), are equivalent in terms of mechanism of action (same fundamental technology): they all provide calcium salt bone void fillers which resorb and are replaced by bone during the natural process of bone healing. All devices have equivalent Indications for Use.
6
Kuros Biosciences Traditional 510(k) For MaqnetOs Easypack Putty
Device Description:
MagnetOs Easypack Putty is a synthetic, resorbable, osteoconductive bone void filler for the repair of bony defects.
MagnetOs Easypack Putty consists of 65–75% tri-calcium phosphate (TCP – Саз(РО4)2) and 25-35% hydroxyapatite (HA - Ca10(PO4)6(OH)2) granules, premixed with a synthetic polymeric binder that provides cohesion between the granules.
New bone will be deposited on the surface of the graft when placed next to viable host bone. The graft resorbs and is replaced by bone during the natural process of bone remodeling.
MagnetOs Easypack Putty is a ready-to-use product. Pressure applied by manipulation allows users to shape MagnetOs Easypack Putty to conform to the contours of bony defects.
MagnetOs Easypack Putty is provided in open-ended syringes in a range of product volumes. MagnetOs Easypack Putty is gamma-sterilized and sterile packaged for single use only.
Technological Characteristics:
Non-clinical testing data submitted, referenced, or relied upon to demonstrate substantial equivalence included chemical composition, physical properties, biocompatibility, and performance characteristics in accordance with FDA recognized consensus standards and FDA guidance documents as applicable.
Non-Clinical Tests (Performance/Physical Data):
Non-clinical testing data were submitted according to the quidance documents Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Resorbable Calcium Salt Bone Void Filler Device (issued June 2003) and Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile (issued January 2016). The non-clinical testing data submitted, referenced, or relied upon to demonstrate substantial equivalence included chemical composition, physical properties, sterilization, material-mediated pyrogenicity, sterile barrier shelf life, product shelf life, and biocompatibility.
Bacterial endotoxin testing of MagnetOs Easypack Putty was conducted and met endotoxin limits.
7
Kuros Biosciences Traditional 510(k) For MaqnetOs Easypack Putty
Bench testing and animal data demonstrated that the safety and effectiveness of the MagnetOs Easypack Putty is equivalent to the predicate devices. A summary is given below.
Testing was performed to evaluate the physicochemical and crystallographic characteristics of MagnetOs Putty. Characterization tests included:
- Product visual inspection
- Composition, crystallinity, and Ca/P ratio (X-ray diffraction (XRD)) ●
- Microstructure (SEM) ●
- Identity (Fourier Transform Infrared (FTIR) spectroscopy) ●
- Porosity (mercury intrusion porosimetry)
- Polymer inherent viscosity (Ubbelohde Viscometry) ●
- Polymer chemical composition (NMR) ●
- . Organic volatile impurities (OVI)
- Water content (Coulometric Karl Fischer Titration)
- Trace elemental analysis (ICP-MS)
- In vitro dissolution and pH ●
- Polymer irrigation test ●
- . Calcium ion release (ICP-MS)
Biocompatibility Testing
Biocompatibility of the subject device was assessed using the methodology described in ISO 10993-1, ISO 10993-3, ISO 10993-5, ISO 10993-6, ISO 10993-10, ISO 10993-11, ISO 10993-12, ISO 10993-18, USP , USO , USP 43 - NF 38 and European Pharmacopeia, 10th edition, 2020.
Animal Studies
MagnetOs Putty is the primary predicate device used for animal performance testing studies. The performance of the MagnetOs Easypack Putty was established in a posterolateral spine fusion animal model justifying that MagnetOs Easypack Putty can be used as an autograft extender (1:1) in posterolateral spine.
Animal testing was performed in a rabbit posterolateral spine fusion model to demonstrate substantial equivalence to the primary predicate device (K181958, K171563). Animals were evaluated after implantation with the subject device, the primary predicate device, and autograft (positive control) up to 12 weeks. Evaluation endpoints included manual palpation. range of motion/flexibility testing, plain and high-resolution radiography, micro-computed tomography (micro-CT) imaging, undecalcified histologic evaluation, and histomorphometric analysis.
Decalcified paraffin histology sections also were graded according to ISO 10993-6 (Annex E).
Clinical Studies
No clinical studies were conducted to prove substantial equivalence as part of the submission.
8
Kuros Biosciences Traditional 510(k) For MagnetOs Easypack Putty
Safety and Effectiveness/Conclusion:
Based on the information presented in this 510(k) premarket notification, MagnetOs Easypack Putty is considered substantially equivalent to predicate devices. MagnetOs Easypack Putty is as safe and effective as currently marketed predicate devices.
It is our determination that the MagnetOs Easypack Putty is as safe, as effective and performs within its design specifications, and is substantially equivalent to predicate devices.